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Background
Brewer’s yeast and baker’s yeast were both Saccharomyces
cerevisiae but different strains [1]. Invasive infection caused by
S. cerevisiae is rare and usually occurs in patients in an immunocom-
promised situation, such as patients with solid cancers or hemato-
logical malignancies [2,3], or patients who have undergone organ
transplantation [2,4,5]. In immunocompetent patients, ingestion of
the yeast has been associated with fever [6]. In this paper, we report
a case of osteomyelitis caused by S. cerevisiae in a young female
baker with no apparent immunodeﬁciency following trauma.
Case presentation
Apreviously healthy, 39-year-old female baker presented to the
emergency department with a distal humerus fracture which was
classiﬁed as a Cauchoix-Duparc type 3 fracture (Figs. 1 and 2). She
had been working at a bakery and her right upper extremity had
been caught in an electrical bakery dough mixer. Surgical
debridement, copious lavage and removal of all necrotic tissues
were performed. The fracture was temporized and stabilized using
an external ﬁxation. Following surgery, she was treated with oral
amoxicillin-clavulanic acid 3 g/day. On the ﬁfth day after surgery,
she underwent a second surgical debridement and reconstruction
of the lost complex humeral tissue using the latissimus dorsi ﬂap.
External ﬁxation was maintained to prevent sepsis, but realign-
ment was performed. Bacterial cultures of deep surgical samples
were positive for Pseudomonas aeruginosa and Enterobacter
cloacae. She was treated with intravenous imipenem-cilastatin
1000 mg every 12 h and oral ciproﬂoxacin 500 mg every 8 h.
On the ﬁfteenth day of her hospitalization, and despite
antibiotherapy, she developed a purulent discharge from the
posterolateral surface of the right arm. Bone samples obtained
from surgical biopsies tested negative for bacterial pathogens, but
fungal cultures grew for S. cerevisiae. Antifungal susceptibility
testing, using the E-test assay, of this S. cerevisiae isolate showed
low MICs for itraconazole (0.12 mg/L), ﬂuconazole (4 mg/L),
voriconazole (0.06 mg/L) and, amphotericin B (0.25 mg/L) and
relatively higher MIC for posaconazole (0.25 mg/L). She was
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treated with hyperbaric oxygen therapy, voriconazole 250 mg
twice daily orally and antibacterial therapy. Imipenem-cilastatin
and oral ciproﬂoxacin were continued. The clinical outcome was
favorable with the disappearance of purulent wound drainage
(Fig. 3) and she was discharged 25 days after her admission.
Overall, she was treated with three months of antibacterials and
nine months of voriconazole. An adjunctive treatment with
hyperbaric oxygen therapy was performed. The skin had healed
after sixweeks. External ﬁxationwas removed after sixweekswith
a humeral nonunion repair by double external ﬁxation (Fig. 4).
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Fig. 1. Traumatic right upper arm wound image.
[(Fig._2)TD$FIG]
Fig. 2. Bone radiograph of distal humerus fracture presenting a Cauchoix and
Duparc type 3 fracture at her admission.
[(Fig._3)TD$FIG]
Fig. 3. Traumatic right upper arm wound image on 25 days after admission.
[(Fig._4)TD$FIG]
Fig. 4. Bone radiograph of distal humerus on 25 days after admission.
P. Seng et al. / IDCases 5 (2016) 1–32
Discussion
Saccharomyces bone and joint infections are extremely rare and
have only previously reported in immunocompromised hosts
[7,8]. We report the ﬁrst case of S. cerevisiae osteomyelitis in an
immunocompetent patient who acquired the infection following
traumatic humeral fracture using a bread doughmixer in a bakery.
To the best of our knowledge, only two cases of bone and joint
infection caused S. cerevisiae have been reported including one case
of arthritis in a 73-year-old woman with rheumatoid arthritis and
Sjo¨gren’s syndrome [7] and one case of mandibular osteomyelitis
in a 4-year-old boywho had undergone chemotherapy for an acute
lymphoid leukemia [8].
Osteoarticular infection caused by S. cerevisiae may be a
monomicrobial infection such as in the case of mandibular
osteomyelitis [8]. However, this infection may also be polymicro-
bial, such as in the arthritis case reported [7] or misidentiﬁed such
as in our case at the beginning of management that was initially
diagnosed as osteomyelitis caused by P. aeruginosa and E. cloacae. S.
cerevisiae was identiﬁed only at the second surgical deep samples
culture. Physicians should consider S. cerevisiae as potential
pathogen of osteomyelitis when infection has occurred in patients
who have had wound contact with baker’s or brewer’s yeast.
Identiﬁcation of S. cerevisiaewas ﬁrst performed byMALDI-TOF
MS from the cultivation of a biopsy on Sabouraudmedium andwas
then conﬁrmed by sequencing of the ITS2 region of the rRNA gene
as described by Cassagne et al. [9]. The antifungal agent of choice
for the treatment of invasive infection by S. cerevisiae is unknown.
S. cerevisiae is consistently susceptible to amphotericin B, to
ﬂuconazole and itraconazole. However, in vitro azole resistance
have been reported [10]. After surgical debridement, oral antifun-
gal agent with voriconazole was chosen in combination hyperbaric
oxygen therapy and antibacterial therapy to treat this patient for
early returning to rehabilitation center.
There is no data reported on hyperbaric oxygen for fungi
osteomyelitis. Therefore, hyperbaric oxygen therapy was used as
an adjunctive treatment of diabetic foot infections and refractory
osteomyelitis for over sixty years [11–14]. In our case, hyperbaric
oxygen therapy has improved the postoperative care for this
complex case of osteomyelitis caused by mixed bacterial and fungi
infection.
Conclusion
Osteomyelitis due to S. cerevisiae is rare, but may occur in
immunocompetent hosts, as our patient demonstrates. The
organism should be considered as a potential cause of infection
in patients who may have been at risk for inoculation with
brewer’s or baker’s yeast, particularly when they fail to respond to
antibacterial therapy and surgical debridement and lavage.
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